FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569180813> ?p ?o ?g. }

• W2569180813 abstract "Abstract Background β-thalassemia major (β-TM) is one of the most common inherited diseases worldwide, characterized by a reduced ability to produce hemoglobin resulting in life-long transfusion-dependent anemia. Chronic transfusions carry significant risks such as infection, and result in iron overload that can cause significant multisystem organ damage. Hydroxyurea, an oral chemotherapeutic drug, is anticipated to decrease the need for transfusions, either completely or partially by raising hemoglobin levels and thus decreasing the short and long term complications of chronic transfusions. Objectives To evaluate the clinical efficacy and safety of hydroxyurea in β-thalassemia major (β-TM) patients of any age. Search strategy We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ongoing trials registers, and major preceding conferences. Hand searches were also conducted using reference lists from primary studies. All searches were updated to June 5, 2014. Selection criteria Randomized controlled trials (RCTs) and observational studies (sample size ≥ 5) assessing the clinical efficacy of hydroxyurea alone for three months or longer, for the treatment of patients with β-TM were included. Data collection and analysis Two authors acted as reviewers and independently assessed study quality and extracted data from the included studies. Authors of included studies were contacted if further information was required. β-TM includes the classical β-TM as well as severe hemoglobin E/β thalassemia, both of which are characterized by lifelong transfusion needs. The effect size was estimated as a proportion (those showing response to treatment over the total number treated) and reported as overall response rate (ORR) or complete response rate (CRR). ORR was defined as ≥ 50% reduction in transfusion need and CRR was defined as complete cessation of regular transfusion. All data was analyzed using Stata, Version 13.0. Results A total of 10 observational studies involving 620 patients were included. Hydroxyurea was associated with a statistically significant decrease in transfusion need with CRR of 36% (95% CI, 23-50%) and ORR of 66% (95% CI, 52-79%). All of the studies had several limitations, such as small sample size, lack of comparison group, under-reporting of data and methods, and being observational studies. Adverse events (AEs) were transient and improved with temporary cessation of the drug and/or adjustment of the dose. No long-term AEs, including cancer or end organ damage were reported. Authors’ conclusion Hydroxyurea appears to be effective in the management of β-TM by decreasing the need for chronic blood transfusions completely or partially in a significant number of patients. It appears to be well tolerated and associated with mild and transient AEs. Patients with β-TM may benefit from a trial of hydroxyurea, though large RCTs assessing efficacy should be done to confirm the findings of this meta-analysis. Disclosures Off Label Use: Hydroxyurea for β-Thalassemia." @default.
• W2569180813 created "2017-01-13" @default.
• W2569180813 creator A5018859388 @default.
• W2569180813 creator A5051477914 @default.
• W2569180813 creator A5063368377 @default.
• W2569180813 date "2014-12-06" @default.
• W2569180813 modified "2023-09-27" @default.
• W2569180813 title "Hydroxyurea for β-Thalassemia Major: A Meta-Analysis" @default.
• W2569180813 doi "https://doi.org/10.1182/blood.v124.21.4894.4894" @default.
• W2569180813 hasPublicationYear "2014" @default.
• W2569180813 type Work @default.
• W2569180813 sameAs 2569180813 @default.
• W2569180813 citedByCount "4" @default.
• W2569180813 countsByYear W25691808132015 @default.
• W2569180813 countsByYear W25691808132017 @default.
• W2569180813 countsByYear W25691808132022 @default.
• W2569180813 countsByYear W25691808132023 @default.
• W2569180813 crossrefType "journal-article" @default.
• W2569180813 hasAuthorship W2569180813A5018859388 @default.
• W2569180813 hasAuthorship W2569180813A5051477914 @default.
• W2569180813 hasAuthorship W2569180813A5063368377 @default.
• W2569180813 hasConcept C105795698 @default.
• W2569180813 hasConcept C126322002 @default.
• W2569180813 hasConcept C129848803 @default.
• W2569180813 hasConcept C168563851 @default.
• W2569180813 hasConcept C177713679 @default.
• W2569180813 hasConcept C187212893 @default.
• W2569180813 hasConcept C23131810 @default.
• W2569180813 hasConcept C2777799968 @default.
• W2569180813 hasConcept C2778248108 @default.
• W2569180813 hasConcept C2780014101 @default.
• W2569180813 hasConcept C33923547 @default.
• W2569180813 hasConcept C535046627 @default.
• W2569180813 hasConcept C71924100 @default.
• W2569180813 hasConcept C95190672 @default.
• W2569180813 hasConceptScore W2569180813C105795698 @default.
• W2569180813 hasConceptScore W2569180813C126322002 @default.
• W2569180813 hasConceptScore W2569180813C129848803 @default.
• W2569180813 hasConceptScore W2569180813C168563851 @default.
• W2569180813 hasConceptScore W2569180813C177713679 @default.
• W2569180813 hasConceptScore W2569180813C187212893 @default.
• W2569180813 hasConceptScore W2569180813C23131810 @default.
• W2569180813 hasConceptScore W2569180813C2777799968 @default.
• W2569180813 hasConceptScore W2569180813C2778248108 @default.
• W2569180813 hasConceptScore W2569180813C2780014101 @default.
• W2569180813 hasConceptScore W2569180813C33923547 @default.
• W2569180813 hasConceptScore W2569180813C535046627 @default.
• W2569180813 hasConceptScore W2569180813C71924100 @default.
• W2569180813 hasConceptScore W2569180813C95190672 @default.
• W2569180813 hasLocation W25691808131 @default.
• W2569180813 hasOpenAccess W2569180813 @default.
• W2569180813 hasPrimaryLocation W25691808131 @default.
• W2569180813 hasRelatedWork W1518392639 @default.
• W2569180813 hasRelatedWork W1806664060 @default.
• W2569180813 hasRelatedWork W1870387638 @default.
• W2569180813 hasRelatedWork W1946552810 @default.
• W2569180813 hasRelatedWork W1993577718 @default.
• W2569180813 hasRelatedWork W2040683981 @default.
• W2569180813 hasRelatedWork W2102779366 @default.
• W2569180813 hasRelatedWork W2118172771 @default.
• W2569180813 hasRelatedWork W2145134122 @default.
• W2569180813 hasRelatedWork W2180855390 @default.
• W2569180813 hasRelatedWork W2470201469 @default.
• W2569180813 hasRelatedWork W2562699034 @default.
• W2569180813 hasRelatedWork W2566072162 @default.
• W2569180813 hasRelatedWork W2900160353 @default.
• W2569180813 hasRelatedWork W2991306810 @default.
• W2569180813 hasRelatedWork W3122128462 @default.
• W2569180813 hasRelatedWork W3177462352 @default.
• W2569180813 hasRelatedWork W3193664958 @default.
• W2569180813 hasRelatedWork W3213613317 @default.
• W2569180813 hasRelatedWork W80357786 @default.
• W2569180813 isParatext "false" @default.
• W2569180813 isRetracted "false" @default.
• W2569180813 magId "2569180813" @default.
• W2569180813 workType "article" @default.